A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Kennedy selected a new team of medical professionals and scientists who are highly qualified and dedicated to public health.

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Regulatory tracker: FDA accepts GSK expansion filing for RSV vaccine Arexvy By Fraiser Kansteiner, Zoey Becker, Angus Liu, Kevin Dunleavy, Eric Sagonowsky Jul 14, 2025 9:35am ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

US biotech Tract Bio has appointed Chris Galloway as chief medical and development officer, as it prepares for an ...

"A regulatory decision by the FDA on this submission is expected in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including in the European Economic ...

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...